ArticleScientific data2018
Small RNA-seq analysis of circulating miRNAs to identify phenotypic variability in Friedreich's ataxia patients.
Article in Scientific data, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Hemolysis Analysis and Hemolysis-related MicroRNA Candidates for Serum/Plasma Samples.Current molecular medicine · 2026Review
- Scoliosis as a Paradigm of Pathological Spinal Curvature: Molecular Mechanisms and Imaging Innovations : Molecular and Imaging Insights in Scoliosis.Galen medical journal · 2025Review
- An RNA-seq study in Friedreich ataxia patients identified hsa-miR-148a-3p as a putative prognostic biomarker of the disease.Human genomics · 2024Article
- Article
- Advances in epigenetic research of adolescent idiopathic scoliosis and congenital scoliosis.Frontiers in genetics · 2023Review
- Transcriptomic Analysis Provides Insights to Reveal theFrontiers in cell and developmental biology · 2022Article
- Blood gene expression predicts intensive care unit admission in hospitalised patients with COVID-19.Frontiers in immunology · 2022Article
- Antioxidant Therapies and Oxidative Stress in Friedreich´s Ataxia: The Right Path or Just a Diversion?Antioxidants (Basel, Switzerland) · 2020Review
- NF90 modulates processing of a subset of human pri-miRNAs.Nucleic acids research · 2020Article
- A Comprehensive Transcriptome Analysis Identifies FXN and BDNF as Novel Targets of miRNAs in Friedreich's Ataxia Patients.Molecular neurobiology · 2020Article
- Oxidative Stress, a Crossroad Between Rare Diseases and Neurodegeneration.Antioxidants (Basel, Switzerland) · 2020Review
- COMPSRA: a COMprehensive Platform for Small RNA-Seq data Analysis.Scientific reports · 2020Article
- Emerging roles of non-coding RNAs in scoliosis.Cell proliferation · 2020Review
- Circulating nucleic acids in the plasma and serum as potential biomarkers in neurological disorders.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020Review
- Whole-exome and whole-transcriptome sequencing of canine mammary gland tumors.Scientific data · 2019Article
- liqDB: a small-RNAseq knowledge discovery database for liquid biopsy studies.Nucleic acids research · 2019Article
- Iron Hack - A symposium/hackathon focused on porphyrias, Friedreich's ataxia, and other rare iron-related diseases.F1000Research · 2019Article
- Assessment of methods for serum extracellular vesicle small RNA sequencing to support biomarker development.Journal of extracellular vesicles · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Friedreich's ataxia (FRDA; OMIM 229300), an autosomal recessive neurodegenerative mitochondrial disease, is the most prevalent hereditary ataxia. In addition, FRDA patients have shown additional non-neurological features such as scoliosis, diabetes, and cardiac complications. Hypertrophic cardiomyopathy, which is found in two thirds of patients at the time of diagnosis, is the primary cause of death in these patients. Here, we used small RNA-seq of microRNAs (miRNAs) purified from plasma samples of FRDA patients and controls. Furthermore, we present the rationale, experimental methodology, and analytical procedures for dataset analysis. This dataset will facilitate the identification of miRNA signatures and provide new molecular explanation for pathological mechanisms occurring during the natural history of FRDA. Since miRNA levels change with disease progression and pharmacological interventions, miRNAs will contribute to the design of new therapeutic strategies and will improve clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.